ResearcherUniversity of Alabama at BirminghamActive in the last 2 years
Aubrey Lynn Miller
Matched on OpenAlex author ID A5028692847. Sources: OpenAlex.
Their work
- Papers
- 8 (first author 3, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 5
2016: 1 paper · 2017: none · 2018: none · 2019: 1 paper · 2020: 3 papers · 2021: 1 paper · 2022: 1 paper · 2023: none · 2024: 1 paper
Papers 8
- The BET inhibitor sensitivity is associated with the expression level of CDC25B in pancreatic cancer models. Co-author DOI 10.20517/cdr.2024.53↗
- The BET Inhibitor JQ1 Potentiates the Anticlonogenic Effect of Radiation in Pancreatic Cancer Cells. First author DOI 10.3389/fonc.2022.925718↗
- The BET Inhibitor JQ1 Augments the Antitumor Efficacy of Gemcitabine in Preclinical Models of Pancreatic Cancer. Co-author DOI 10.3390/cancers13143470↗
- Developing effective combination therapy for pancreatic cancer: An overview. Co-author DOI 10.1016/j.phrs.2020.104740↗
- Development of gemcitabine-resistant patient-derived xenograft models of pancreatic ductal adenocarcinoma. Co-author DOI 10.20517/cdr.2020.35↗
- Patient-Derived Xenograft Models of Pancreatic Cancer: Overview and Comparison with Other Types of Models. First author DOI 10.3390/cancers12051327↗
- The BET inhibitor JQ1 attenuates double-strand break repair and sensitizes models of pancreatic ductal adenocarcinoma to PARP inhibitors. Co-author DOI 10.1016/j.ebiom.2019.05.035↗
- The BET bromodomain inhibitor JQ1 suppresses growth of pancreatic ductal adenocarcinoma in patient-derived xenograft models. First author DOI 10.1038/onc.2015.126↗
Closest collaborators
The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Patrick L. Garcia · 8 shared papers, 2016–2024 · strength 1.25
- Paper The BET inhibitor sensitivity is associated with the expression level of CDC25B in pancreatic cancer models. DOI 10.20517/cdr.2024.53↗
- Paper Developing effective combination therapy for pancreatic cancer: An overview. DOI 10.1016/j.phrs.2020.104740↗
- Paper Patient-Derived Xenograft Models of Pancreatic Cancer: Overview and Comparison with Other Types of Models. DOI 10.3390/cancers12051327↗
- Karina Jin Yoon · 8 shared papers, 2016–2024 · strength 1.25
- Paper The BET inhibitor sensitivity is associated with the expression level of CDC25B in pancreatic cancer models. DOI 10.20517/cdr.2024.53↗
- Paper Developing effective combination therapy for pancreatic cancer: An overview. DOI 10.1016/j.phrs.2020.104740↗
- Paper Patient-Derived Xenograft Models of Pancreatic Cancer: Overview and Comparison with Other Types of Models. DOI 10.3390/cancers12051327↗
- Robert C.A.M. van Waardenburg · 3 shared papers, 2019–2022 · strength 0.42
- Paper The BET Inhibitor JQ1 Potentiates the Anticlonogenic Effect of Radiation in Pancreatic Cancer Cells. DOI 10.3389/fonc.2022.925718↗
- Paper The BET Inhibitor JQ1 Augments the Antitumor Efficacy of Gemcitabine in Preclinical Models of Pancreatic Cancer. DOI 10.3390/cancers13143470↗
- Paper The BET inhibitor JQ1 attenuates double-strand break repair and sensitizes models of pancreatic ductal adenocarcinoma t… DOI 10.1016/j.ebiom.2019.05.035↗
- John D. Christein · 1 shared paper, 2016 · strength 0.05
- J. Pablo Arnoletti · 1 shared paper, 2016 · strength 0.05
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.